No Data
No Data
Amplia Therapeutics Completes Enrollment for Phase 2A Pancreatic Cancer Trial; Shares Up 3%
Amplia Therapeutics (ASX:ATX) completed the enrollment of 26 patients for its phase 2a clinical trial investigating the use of inhibitor narmafotinib in patients with pancreatic cancer, according to a
Amplia Therapeutics Hits Key Trial Milestone
Amplia Therapeutics Ltd. (AU:ATX) has released an update.
Amplia Therapeutics Ltd: Preliminary Final Report and Annual Report YE 31 March 2024
Amplia Therapeutics to Raise AU$4.3 Million for Cancer Trials, Drug Capsule Manufacturing
Amplia Therapeutics (ASX:ATX) is seeking to raise AU$4.3 million via a nonrenounceable entitlement offer of 77.6 million shares at AU$0.055 per share, according to a Tuesday filing with the Australian
Amplia Concludes Phase I Trials of Anti-Cancer Drug; Prepares for Phase II
Amplia Therapeutics (ASX:ATX) provided an update on the clinical trials of its AMP945 anti-pancreatic cancer medication, saying response rates from the first stage of the study "continue to be substan
Amplia Therapeutics Updates on Pancreatic Cancer Trial; Phase-Two Recruitment Ongoing; Shares Up 3%
Amplia Therapeutics (ASX:ATX) reported "substantially better" response rates from the first phase of its pancreatic cancer drug trial amidst ongoing patient recruitment for the second phase, a filing
No Data